Antisense Drug Targeting c-myb Oncogene Starts Phase 1 Trial in Patients with Advanced Cancer
New Genta Pipeline Drug Targets Master Regulatory Gene for Cancer Cell Growth
17-Oct-2006 -
Genta Incorporated announced initiation of a Phase 1 clinical trial using an anticancer drug derived from the Company's DNA/RNA Medicines program. The new compound, known as G4460, uses antisense technology to target an oncogene known as c-myb that regulates key functions in cancer cells. Using ...
apoptosis
clinical trials
dosing
+8